Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Starts Global Phase III Trial of BTK Inhibitor

publication date: Jan 27, 2017
BeiGene has started a global Phase III trial of its lead molecule, BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor. The candidate will be administered to patients with Waldenström’s macroglobulinemia. WM is a rare disease, though ultimately BeiGene will seek approval of BGB-3111 for other forms of lymphoma. In the trial, BeiGene's candidate will be compared to Imbruvica, an already approved drug. BeiGene believes BGB-3111 will prove to have a better side effect profile than Imbruvica because it is more selective. In earlier trials, BGB-3111 demonstrated an overall response rate of 94%, including a major response rate of 78%, at a median follow-up time of 9.6 months. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital